-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Sw/QN0h9NwlGuoxXi3Ma4cENbQZNf98klNpLdJiIirhqgS7Lpzt6XGz/r1OIulRr
 phpB5LdotE/52RU8wWpa9g==

<SEC-DOCUMENT>0001144204-07-049782.txt : 20070917
<SEC-HEADER>0001144204-07-049782.hdr.sgml : 20070917
<ACCEPTANCE-DATETIME>20070917164431
ACCESSION NUMBER:		0001144204-07-049782
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070917
FILED AS OF DATE:		20070917
DATE AS OF CHANGE:		20070917

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		071120549

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v087854_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      September 17, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt="XTL Biopharmaceuticals Logo"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
        by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated September
        17,
        2007 is hereby incorporated by reference into the registration statement
        on Form
        F-3 (File No. 333-141529) filed by XTL Biopharmaceuticals Ltd. with the
        Securities and Exchange Commission on March 23, 2007.</strong></font></div>
      <div align="center"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
        BIOPHARMACEUTICALS PRESENTS A NEW CLASS OF HIGHLY POTENT <br>SMALL MOLECULE
        INHIBITORS OF HEPATITIS C AFFECTING THE NS5A <br>TARGET AT AN INTERNATIONAL
        SCIENTIFIC CONFERENCE</strong></font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
        Cottage, New York - September 17, 2007</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        XTL
        Biopharmaceuticals Ltd. (NASDAQ: XTLB, LSE: XTL, TASE: XTL) announced today
        that
        on September 13, 2007, it presented a new class of novel and highly potent
        small
        molecule inhibitors of hepatitis C affecting the NS5A target at the 14th
        International Symposium on Hepatitis C Virus &amp; Related Viruses in Glasgow,
        Scotland (www.hcv2007.com).</font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        an
        oral latebreaker presentation, the Company described a family of pre-clinical
        compounds with highly potent activity against the hepatitis C virus. Potency
        of
        these compounds was evaluated in a replicon assay which is known to have
        good
        correlation with clinical efficacy and is the current gold standard for
        pre-clinical testing of inhibitors of Hepatitis C. In the replicon assay,
        the
        Company&#8217;s most advanced compounds had single-digit nM (nanomolar) potency
        against hepatitis C genotype 1b and low double-digit nM potency against genotype
        1a. Genotypes 1a and 1b represent 75% of the U.S. hepatitis C population,
        according to the American Liver Foundation. These replicon potencies are
        superior to the most advanced clinical-stage small molecule protease inhibitors
        of Hepatitis C, which to date have reported triple-digit nM potency against
        1a
        and 1b replicons. </font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Data
        presented by the Company implicated the viral protein NS5A as the direct
        target
        of the compounds. NS5A is essential for RNA production and is distinct from
        the
        protease and polymerase - the viral targets of the more advanced Hepatitis
        C
        inhibitors in clinical development. As such, inhibitors of NS5A are considered
        promising candidates for the treatment of Hepatitis C. As a relatively new
        target, only one NS5A inhibitor has entered clinical trials to date - A831
        -
        which is presently in a phase 1 clinical trial. A831 was developed by Arrow
        Therapeutics, which was recently acquired by AstraZeneca. Based on data
        presented at the conference, the Company&#8217;s leads appear to be over 10 times more
        potent than A831 in the replicon assay. </font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        rodent
        studies, when administered orally, the Company&#8217;s compounds demonstrated
        preferential accumulation in the liver to concentrations that were orders
        of
        magnitude above those required to block viral replication as predicted by
        the
        replicon assay, with half-lives consistent with twice a day dosing regimen,
        and
        toxicological tolerability at multiple doses. </font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company also presented data indicating an additive effect with interferon
        (the
        current standard of care) and with the protease inhibitor VX-950 and retained
        potency against protease- and polymerase- inhibitor resistant mutants in
        the
        replicon assay. These findings are supportive of the potential role of the
        Company&#8217;s compounds in combination with interferon and other small molecules
        currently in clinical development.</font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr.
        Ira
        Jacobson,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Professor
        of Clinical Medicine</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        and</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Chief of
        the Division of Gastroenterology and Hepatology at Weill Medical College
        of
        Cornell University, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
        an
        advisor to the XTL-DOS program commented: &#8220;Chronic hepatitis C represents a
        tremendous unmet medical need with millions of patients seeking safer and
        more
        efficacious treatment options. Future treatment regimens are likely to include
        combinations of novel small molecules with interferon and ribavirin, which
        may
        eventually be replaced by cocktails of several small molecules employing
        complementary mechanisms of action. The preclinical data presented by XTL
        suggest that the Company&#8217;s compounds could prove, with appropriate testing in
        clinical trials, to be very attractive candidates for incorporation into
        future
        treatment regimens in combination with interferon-based therapy and/or other
        small molecules presently in clinical development.&#8221; </font></div>
      <div align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        molecules presented by the Company emerged from the Company&#8217;s DOS program, aimed
        at discovering novel hepatitis C inhibitors applying a unique chemistry
        technology called Diversity Oriented Synthesis. The DOS program was acquired
        by
        the Company in late 2005.</font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
        HEPATITIS C</strong></font></div>
      <div align="left"><br></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There
        are
        approximately 3 million people infected with hepatitis C in the U.S. alone.
        Hepatitis C significantly increases the infected person&#8217;s risk of developing
        chronic liver disease, cirrhosis and liver cancer, and is the leading cause
        of
        liver transplantation in the Western World. Hepatitis C remains a major unmet
        medical need as the current standard of care (interferon-based therapy) achieves
        success in only 50% of patients infected with genotype 1 of the virus (genotype
        1 affects 75% patients in the U.S.), and has significant side affects associated
        with it.</font></div>
      <div align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
        XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: -9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
        Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
        for the treatment of neuropathic pain and hepatitis C. XTL is developing
        Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
        of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
        hepatitis C small molecule inhibitors. XTL also has an active in-licensing
        and
        acquisition program designed to identify and acquire additional drug candidates.
        XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
        (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: -9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
        Bentsur, Chief Executive Officer</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
        +1-(845)-267-0707 ext. 225</font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
        Statement</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
        of the statements included in this press release, particularly those
        anticipating future performance and prospects of our pre-clinical compounds
        for
        hepatitis C from our XTL-DOS program may be forward-looking statements that
        involve a number of risks and uncertainties. For those statements, we claim
        the
        protection of the safe harbor for forward-looking statements contained in
        the
        Private Securities Litigation Reform Act of 1995. Among the factors that
        could
        cause our actual results to differ materially are the following: our ability
        to
        successfully complete the pre-clinical development DOS program; our ability
        to
        clinically develop candidates from the DOS program; and other risk factors
        identified from time to time in our reports filed with the Securities and
        Exchange Commission and the London Stock Exchange, including our annual report
        on Form 20-F filed with the Securities and Exchange Commission on March 23,
        2007. Any forward-looking statements set forth in this press release speak
        only
        as of the date of this press release. We do not intend to update any of these
        forward-looking statements to reflect events or circumstances that occur
        after
        the date hereof. This press release and prior releases are available at
        http://www.xtlbio.com. The information in our website is not incorporated
        by
        reference into this press release and is included as an inactive textual
        reference only.</em></font><br></div>
      <div align="left">&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">

    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              September 17, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron Bentsur</font></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2">&#160;</td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cheif Executive Officer</font></div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0"D`P$1``(1`0,1`?_$`,T````%!0$!````````
M```````("0H+`0(#!@<%!`$``0,%`0``````````````"``"!P$$!08)`Q``
M``4#`@,$!@0)"`L``````0(#!`41!@<`""$2"3%!$Q1182(5%@IQ,A@Y@9&A
MP6(SLW9WT2,DM+76EUCPL?%"4F,U1387&1$``0($!`(%!P8*"`8#`````0(#
M`!$$!2$2!@<Q05%A<1,(@9&Q(C(4%:'!<B,6-M%"4I*RTG-4=!?A\6(S@Y,D
M&/""PD-3-"4F"?_:``P#`0`"$0,1`#\`?X%/S4]H1Y@J%![::\0D#VG)B*!:
MC^)*-+R1?D#BZP+XR5="JJ-NV#:-PWC.*I%%18(JVXEW,/RH$[3N#-F9@('>
M:@:]J2FJ+A5MV^D("G5!()XS)EYH\:NK;I*1=142[M`)('4(9(3GS8N61S46
M9MO;U;1]O:,D9((!V^`<@RD"1X*2<PE<7B%9,EG,?1<&YFAC$,/()A'CHG:/
MP[BILB<]=_\`+A&8S'J2E/#^O'C$'O;P%-Q4RA$J1)E(@S"I\.'DX<>?.'F^
MW7.-I[D,'XYSE97F4[9R5;$==$:S=T\ZP3D42+&CG8@!0%RS,;D/P"HAV:&J
M\6RIM5VJ+8^Y,L**20,,/FB9K37MWBWLUJ?52\F<OFCM0FY:`(#6O"H@%.SB
M'JU8I<4@95%(5YHR)!7)67A%P5[N;\6JI"/^Z$YNJ$3FQ(/GBOM?I?BT[ZCH
M$4E]+SP/:_2_%I?4=`A2^EYX'M?I?BTOJ.@0I?2\\6^(`&Y1K6E>(<*"-/R:
M;G:"LJ03V0BE/%2I#H,92B`CP`.SM#7MQ$-'=YO5XQDU2'Q\5033`!JH%>P`
M[`[N'=KP+BF7"MXDSPP&$,S.M"7K..<^F/H1$!*(@(CQ_P!X:B'`.'=33V^$
M\V8$\82)2PG/G/C.+CE`P4'TUTG4YDRZX<4@\8^8Q^4]"B!0`*B'I^GUCJCB
MW%HDV,>F**0ZI0=4L!L0`,54"\IA`*B%!#VN'\O=J@J&F7,BU36J/0H2,%IS
M'ICZ$Z`6@5X#3C_L#5PKC.&R`P``'5&3384#2A0-*%"+?6T/O6LO:NKF[9-E
M>X[`NK#CU>?OZW8!LP<FNRQG":1)5T!7C!^8'-N(H&7(4H!XG.(!V:WS;=K3
M=3J%%!J=`50OX((D,JN6:?*-.UP;RQ:U5EG<4EU/$=7DAG=MPZY6[F8RE&65
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M5PWNHHYCWIB-95Z@"C4H"'*0XUJ(ZR&G]J[9>:5>H=8MRN%Q45@#`-@XX@QC
M-0ZUKK+5MV>R.`4=,`$RG,GK,Y&%H-K.9NIC$=*+=#OXW'[EKS5N&XL8R4SM
MWMN290K5Q:L7&D6,CD%TM[H01,>X05`&R(@(I^7$3A[0!J(M26?1CVX5%I'3
MS:/=RL!YPF:<.($N'7/IB0;77:A:T=57:XK6JXH$VP,!VGCAR$CRX#A#:Y#K
MT]4`$4Q-O%NT]4TQ$WAVG41$@"(_]%[Q'1`HV?VY`!4EI24@3Q&)EC+&(G.N
MM<S(2XXF1(D4GICT$>NSU3G!!60W<WFLC7EYTFMKJ%`WH$Q(,Q:_AUZ?RBVY
M?3.EI<PG*<P8M7-R-8,J[IU]0>E.13+#RQC4Z\'5%0/X:^\"[D3T`>15"UDS
M4$*E$2G@Z\=>:MH=NVE=V\TVAP])'X8]&MQM9K3G2MU:.I/X)Q:3KQ=4510$
MD]X5V**CP*FFE:AS&'T`4L)S"/T:>QL[MRM:62EE3B^&4_TF'.;AZU">\"W4
MM])3_5!\^F9U>NHGG/?7M[Q9E#<K=UU6'=UT&87';[MK`IMI-KRI#X*QFT.@
ML4H#7ZIP'B.M5W#VMT?8-*UMRMK.6K8;FD\ISC.:4UEJ"[7QBFKWBIMQ821U
M$$],N42')/KCQX!4`#NH`^C0:GB%<\8)0`!&`'&,VG12&V5\;P=R$7U5(C!3
M#*<XVQ4\S?;MJ*V@1./\B,$_7`CEB"AF8N>0Y1_XZ^O1QVC:+1-5X='M=/TY
M5J!-K>?"\)9T":?)TQS:ON]6X%/XLV=OZ2L6G32[LU3J;_L+("NJ?1A#D5,]
M!.6GL@8P`/=P&E-`OD#)F"`@B<NN.DBE26$2/`&?;%5#CP"H!7@'>-=5&9P^
MJ1DYQ216O)/""P;R)O(MM[;<M3F)QF`R-'6FX7M(;>9GD)?WL5TT*EY)DF@Y
M477%(3T`$S<.[6X;?4]IK=84%'?%)1IUQ\!Y1(!"<<9G#SQ'>[3FH:;;JZ5N
MEPI6H&6"JG2)XJF)3EB?)!/NE=D/=#D#'^07>YM:^%IYE<1$[?\`C>"6@7A(
MPYE:@V06CHXRR0@0*&H;AV]NI)W^LNWECOE$SH);3]&XP%+*%)5)7/%),HB7
MPOW?<RZ6"M7N;WPJVGLK?>`@Y<>D=/#JA5],_LCPI3T]M:?GU!"BXI.9(D>B
M">FC$H([OIZXJ90_"E*"'>`U'UZ1"^[GP7#P`49DD$Q=S#2O,4/IU5M*P).2
M)ZHJ)$8#&,O=_I358;'ERL0PFH]]$RC)K(QDFT<,)&/>(D7:O63I,4G#9PBJ
M4Z:J2J9A`Q3`("`TTU!<:=#S9DY,8]$NB*.H;?94RZ)H4)1&3]<+IHR6P;<Y
M*2]M,SN=OV<I29N3';DB"HH6^]="H\FK->N!(5$7C=4RRR=/9\`Y0"G9H\-I
M=>'4^GFZ-R2KK2^HM)QFW+`CG`L:_P!,U&G[B:AC_P!1U69)'$$&?G'5!A\=
M]<^_K(Z2ER;-Q?2RVX1"4'&-FWT9VL99#"\M'*/7<NLL8XG3=P@@$*BD4:"V
M/S4X!36;CM'3O;@B^-%L6M0[THECW@/"7"1XGKB]9W">:TJ+8@K][0<@,Q[$
MN$SC/HY03;HZ=/"3Z@&[2U;7G6+PV$,;/V=XYBFDB./+O8J-.1RTM(DCRF*C
M+3:HD$HB(\R:9ZZW#=;6C6B-**6C*[=*A.5"`<4`B4P.H8X1B]`::^T]V]YJ
MI^[H,U3XF71V\,>7*)/0V-[(/9C?':]IVX^L-M$-8$EG2$+&O+;-#M&Y&R,<
MI#.&JD:HT\(E!3,F)/5QT!OO-0ESWEE135@S"YD*F>./&"I##*6/=<H+)$I=
M4<K':-M5)RTVR[?@H`%*!<.X\Y0``X!_XX`T#T:O1J#4"02JLJ,>AQ?ZT8I=
MAL^8*-,T0#^2/P1'S_,<V596/^HC(VW85HVO8\$ECNW'`0EGV[#VS$>.Y:,5
M3K^[H5FR:"L83#4_)S#7MT96P=2]4Z:-77NN._6J3)1*C@>DDF!YW6IZ6EOW
M=4S24#NTGU0!B9GEPA>CY9;!>%,E;";DFLBX=Q9?LVCE^[&B4Q>>/[3N:5(T
M([6\)L62FHE\]\!(H`!"<_*4.``&H@WUNETHM8"GHWW6V^ZF`E:DC$\Y$8QO
M^V-JMU;IU3E2TA:BN6(!Y0>OK.;;-O=H]-G<Q/VE@G#5J3\=9IEXZ=MS&%DP
MTPR6*8P<[24CH-L^:*<?KIG*8/3K4ML[Q='M=6YE^I?4@O`*!6HB1ZB2(V+6
MUHMM-I1\LLMI6A,YA(GAT&&-71N$P]2?:B)AYA^+25&A0[$$0[NWZ1XZ+7=9
MH-:%N@!F"B8^2($T(0=3TTN`?'H7$K$'ZT?PZY[\QY?28+X>QY8S:=#(:`YI
MN")M;K)(W///THF`MO/EN3,S).#)D09Q[%45':ZISC0"$)V]^NF>E6JFN\)#
MM/2-..5#EM=IT)`F5+<P!`Y@<^<<?=;5E!9_&C\5KG$M4=-=VWW%*,@E*/65
M,])'#E!Y\H]<-PK<,I$[=<`3F1(F*D7C!U<5P-YXT>_!LX4;@[CBVDA('2;K
M*$'E\;E-3CJ#;)X4%NVQBMU7>Z*WUSS:5!I13-(/`*S2.;IPE!':B\:;K5T?
MH]%:=K;K;FG"GO@%$$CFG)^+T8SCH&WKK98RR!<\+9&;+`E<33\M)MXD9I%4
MZ]JLI!RH5LW0?)R8ISK,5%S%*!CH@4*\:<1UCM;>$K5-@T^[JBPU]-<K8P)J
M;;Q<(Z4Y9@X8QE-`^-+3.I-0-:6U1;GK3<'B`%K5)"23*2LV/5"L6<LPQN&,
M-WUF=:/<7!$V1;JER&91:Z/C2S5)5NDF1DX%0&XD6*X`P&YJ"`:&32%@J-6Z
MDHM*MS8K*NL+*2H2"3CBH<9805FM]9T^B]'7'6"&_>F*2C[\!)!"TX<#Y8X1
MLAWJ0F]2RKDOB`LV9LUM;DZX@58^:<MG2[E4@@`.4S-E5DR)"7C2M=;[N[M-
M4;2Z@I;/7U(J:AZF#@4D$``\C/&<:1LCO)1[RZ;J+U34JJ8-/Y"DD*/3,2)P
MEYHT?>%U*,'[0GJ=M3A)*^\@.$5%O@^U7#(7444$^9NM-+N7"*#5)53V>3F%
M7]$*@.LAM9L3K3=3O;A;O]+9*=/K.NS"29F>0RQ,L>B,!O#XCM$;0)%!6GW[
M43JB$T[,LR<!(KZ!/#IA,T_6YS\*WOLNTHGP&8?'3ECI7X+LK/FYO$.L1@:+
M,<4N(&!04Z]]-38WX4=,Y@T[JFE3<SADFF0)ZIS^2!U'C:U9D]Z^R-6;?F]H
M)<`R],_9ZX4TV<=2C"&[Y=2V(5.4LK(C=$JBMF70LP([?`0H>.O#JMESINT2
M'X`01\4`[0X#J'-T]A-7[3N)K:]::RR.":7V@2CJ!F)`_)!(;/>(W1N[Y7;J
M+-07QN0++I&92N81S,N!'5"C_,6G:'9^;4)YAQY0068>S,9HOKJL.A%GKW8?
MP-E3IUY<?YQN9I9)<?-T;JQ]=BG(9ZSODIBH1<(R1.8`6-=:I4V"@`',4BO-
MV%XR)M5<KM0:S819B55#IRK3_8)Q)Z)=,:1N!2TM3IQUQ^6=H%2>V7*(POQ5
MQ;)G4+R+BW)S%Y0$Y53)`;E,;M'E-P`!T?[YI<B6I'WU2?(%RZ>V!$]IU009
MM9S(](!^<8Q)1_+K6SMIANGI:,M@-^24N6X9J45S1(R";=&XDL@-5_#>Q<BB
MFJJJG%QISJ$C^;@9$1$.\``7==Z]KU<ZQ>"H*;/J#'*4\B#P/7*"MV\IJ!BP
M-N4V7OW?:E(GEYO+"^^HVB18PJ]WTZ:OV8\W/9\T1P?S-'WETM_#6T_[/8Z-
M;8'[FG^(7^E`S;N_>3_#1^BJ'#7RL'W?%T?QFN[^M+ZAS?[[\)_AQZ8DO:;[
MLG]K\PA0'K??=A[H_P!R5/V@ZTO;#[_V_P#;I^>-CU[]U:SZ!B/^Z-WWDVU'
M]["_L4=&?NX/_HMR_9#YH''07WFI_P"('_7$K$'ZT?P_ZM<\>8\OI,&`/8\L
M9M.AD,E-^5INK^ZD^0["8*&(O>64(RWFQB?7!:36(B`E'M`0_-KJ[M!>&['L
M#17BL(31T5O6XD<E*`)$_-'$??.S5&H/$Q=K"R,U1679MN8XA*BD2'D./9#N
M;!NWG%F#L>6[9EBV="Q",="Q[=Z\*S1-(2;H&Y#NG$D]$A5WBRCDYAJ<1IP#
MNUS%U-K&^:JOCUWN54XZMQY2TC,0$()P`'"0CKYHW0>G=&:>9L=EI&FN[80E
M2BD$K7E$R2<2281IZT6T6Q$,7L=R=BP+"U[FM>328WLK#MDFC2<A)!8$VKMV
MU1*1,9-O+K)T7&I^0*:*OPB[G71C5#VA[FKWNVUJ?4S*)R'@1CR(Y0&7C4V>
MLSNEV=P[.V*:\T2P%I2`D+!,RK#F.,;9CG,\GFCHW93?3[DSJ;M"P[BLMZJ<
MH`8S6!E(]G%&.;F$3J':)!4W?2NL3?\`2;>C/%7;[4A`13/W!#R`.6<*)`Z)
M1F+#KG[=>#6Z7%;BA74EN6PX3Q]0H$_+&A]&F^8_&>T#<-D26`1C;*G;AN-Z
M0H\IC-HIHJZ5`!#B'!/6P>+JSNZDW0LMII#]>^TRV.TJE+Y8P'@PO*--[3:A
MOE09L404X?\`E:4KYH)OTZ\#I[Y]VF3,S9E(>X+5MR6<W;,LW2@BVGIN4DEV
M\%'+$$#@9BQ;M43'2XE.%0$*#J0M^=6L[-[86O26F5K8JWT!ES+^4$@J5RXY
MI3B(?#?HM>^N\-TUUJ8*?H*=9>0%>R0I9"4XGB)<(=??!EJ(PA+<+;D*$"5L
M#)*!!BW]S@R!/P@:`Q\,6X(>'P$O+2G=KG6Y<*[WL5:JI\5:C/,5'CQ_XQCJ
MZ;)9E49H11LFB2F64H3+T'E#3OJ2X(4V1;M+#S3A@XVM!72Y0O.$9QQ@21@9
M>)?H(S\>@1,"`G'27FE#$3"@$+0`"FND>P&K6MYMM*_;K62^]JJ=M24+5Q(*
M3EQZ00,8Y2>([2E1L/O!;=Q-(9&K75.)<0A/_D!]<$8"1F90Y'^TA$_9!^U!
MX0>0_P#4_P`?>6_Y_N[G\#DK];S7"F@,^PER_F#_`"\D>_\`?_=Y\_;E.?T<
M8Z,?S$H?Y5?S.D,OPWWF7+-EX2^E\D&F5*0"`(CPI2O-R@`>DPCPIK0PM:`E
M+>.8Q*10A:R\N4@(CY/F+NJ!&;G<M,]J&&9LK[#^$)N0-?4VU2$C.\<B)H"S
M7:(K<XA(P4,D8O(-`*5TF8>T-&#L=MTY:J8ZM=]2Z5`RA)PDUQF>TP.6YNKF
M:]X62D/U#:R9CCFX8&$R[?Z6.X:Y.G5</4):Q2Y;1AKX38L[1$AC3,EC-JR4
M:S-_$;@7Q0"/NGD9IH4J=`PJ@:@4U)#FYMAI]7_9!]P$+:(*N07,>K/IC56M
M&73X!\9;3ZX5A]&7'T09'H/=1HVQ[=7&6GD.YE8S;QG%XQM>]4G`'7C("Y5J
M-;=O!8I3`9HW8F,9%80*;F\<!'LUKF\^WR-3Z<^)4(S55(,R)<5#F!Z9QE=M
M-0&P7GW*JD*>IP6>$L<"<<3,RPQE$EVS>M7S5L\9JD<-'B"+ILX2'F26;N$B
MK(K)G`1`Q%$S@(#H%AWWO!IZD26.'D@I&W$/([QHYDRC,(A2@!0`-^/UZ]<Q
M4DSY&4>:U%223QF!$<-\S1]Y=+?PUM/^SV.C8V!^YI_B%_I0,V[OWD_PT?HJ
MAPU\K!]WQ='\9KN_K2^H<W^^_"?X<>F)+VF^[)_:_,(4!ZWWW8>Z/]R5/V@Z
MTO;#[_V_]NGYXV/7OW5K/H&(_P`Z.(E#J2;3A$W'XN$`+W_J4..C2W<=>.@J
MYA"FPG(,#QY0.6@E$:C9^K"AWXQ\JO1\\2L(\%*\>`FI00&O$>T*\*:YV!W)
MF29>B"]*SE(/##AQB\#\>PWY/Y=-+PD<!YX\Q*?XT,^,VNV#'K.13F4,0D>C
MN/LE1TJ?BFF1)\!A,81X`!1[==-=*4]0[X2BRR)U:;.3(=BHX\:J?9HO&>:A
MXRIVM1I<)^DML^D0\!**:A2F`0,40`Z9@[!*<`,00$.%!*(:YEN!:62D?WAP
M^7G'84K8>4%JQ(D1Y0(2YZP\[$QFQ/*,:_<@W=W$O`QL0B8*"Z=-YV.?+I%J
M-0$K5L<]?0&I[\,=OJ[KN]:RVGZMHE2NP`X]D##XP*VGHMF*]-0L"H?=;2V.
MGUDDCR`3A.S:5!O8KHV[EI1VB9%K/-KQ<1QCCQ5192[1N=0I1[`$YPIZ=3WN
MM64-7XO+4BC5F;144P5VY%0.FT-%6T?@PU"[4((+C52I$^8*TXQK?3HAI&X^
MFIO7@X8JAY63B;Z:L")!_.J+'B5^4A`#C500I^'5SX@:UFW>(73U7584;3C*
MR>I2T^B46'AJMS]R\-VL*.C&:M?I76P.<ULD>B-XZ"-PPS0N=+,56(6XB&AI
M7RO#Q%6/FUF2ABF$0$QDG29N8*<`"NL3XVJ-\JLUPI@3;LQ,^4R$GT1DO`'>
M&&3?;,^0+BD(6$GB9$@RZ9$"'(O,0I!$0$.(5IQ,(C0.&@9<:<<(*"`9S\D=
M)BZEA.<B8D#ATF&V_7QN*(5=X,M9-0AYT65P20-RT%0C3S[1L4AQK4HK*&`0
M"G'1V>"YNH;>O%T0DII^[",QX3D21\D<UO\`]!+FPXNQV5M055**EJ2.(!P'
MG)@[/PU,_P#QS]P^2-[W^S3XODJ#XO+Y3Q^6E*\_A<::B3XS;O\`<Q\1S?Z#
MXU/-RXRGYXG3X+5_[/\`X5W9]]^SOL\^'X(X-U[NI9&;&]KBU@V7<[-CG_.Z
M3NUK.9MWK="5MVVE$13N2[#\ROC,%&C-P'E#F*`**%,`=FH]VGT*YK*^!#^5
M%K9&968R)ZL>,3]K;4+UFL9]T255B\.!,@>SM$NV&'_3TV?7EU#-V5DX-MUT
MG(M9F9+=65[E<.^<L=9;>0"1NIX\<%.*@R$VW!RB@:H5<'"E>S19ZOU50:+L
M+CR5HSMM]TVA)F292!,#UIG3=7J*](2ZAQ`*LRB<.!F9'I&!Z8E2H?!.,[>P
MFQV^1MLQJ6+&=AIXW"W#LVIF2MNDA0A#>80\($572R!?$.IR\QEO;^MQT`:;
MD_4W==Y6M?OA>[P&9XS\\H+=NWT[5O%M0!W"6\@'5*7GYQ%X]5#8I<73TW8W
MEBZ30*UQY/NU+OPU-^()6S^U'CCQV;!NX.<H#(6Z(II+``B)#B&C_P!O=:46
MK-*)-6\VFO;3D*3@)C`S!X]1@3M66*KLE]4.Z66"<P*>@XC'KGCT0[X^7-ZH
M\3N>PPSV@97NQ)_G["<*J2VWCY^@N^O[&;`"$8O$%A.9:1EH!/F!Z;VN5,Z=
M:!30M;P:+8T]?OBE"4&@<,_5/!1X^0Q-FV^J7KE3"WUB5BK2F8F"!(<L>C&'
M/`%.-`$2T*/KK3UB(ZB%80I)R\3C$F/36L9)9.<1OOS-;MHCU,)9-=R@BH.-
M+5,4BJR:9A*#!@',!3&*:G'MT9NPKC5/I%1J7VT-]^H@'`XGM@:]V*>H7?R\
M&UJ;[M(F`>("H<-_*MKIK]/6ZCHJI*E#--WE`Z9RJ$$0>+A2I1$*AJ(-^WF'
M=;A;"PMON!B(DG:MIQO3I;4E25YYR5V0H'UP%`2Z86Z8ZQB)IDLDXF.<P$*7
MVQ$1,8P@`!K3=M"E.N[:YF"4>\)F3T1GM=$_91\*25+4F1`ZXC!<39AN["UZ
MVKE'&-XFM*_+24*]MVY8QRS!_%NC)E`R[;QP72`X@`?6*(<-'K=FK->:1ZVW
M$LNTKF!,\988<8%*FJ+G:ZX5-`AQ#B%3Q!/K`G'E"C@]<WJ=B83?;/R'4W$:
M.[;#\@1```?1PUH*=L-M0)>[L$=HC85ZWUPMPN!YX*/0DR@#US>IX`"(;T,B
M5IP_IEN=O=_VC2.V&VI!`IF)RZ1"&M]<@@]^_P`?R3!S]N60\Y[JYJP[]D+M
M<Y"W`7I(IS2<[)OF24O-W%'G(JU$%&Z:*7G#&-[`%)Q'NT1UD>T;H[:A-!?'
M`S95TIIW$@YE)0<)B7/'C'/;<&WZNU!OS4U5D86Y?#4IJ!@0%+1C+^B'1N(>
MMMB.W[4C[0W%VC=]CY0M9!.!N9LRC%9`CF5B_P"A+KBP22\['\Y40,(*\35J
M'`0T$^H?"WJBXU*KMH*HI:O3U2HK965@$!6(2H3Y0;^EO&=I.@MXM6XM%6T&
MH:63;H#94E10`,PD,)RX<83WW8;H,I]4[)=G8/V_V/,CCZ#FP721%5-859!V
M8S=:X[I?MB>6AHYM%JG%--QRCST*`B8>,[;8:!T[X=;+4ZSU]7,'5):(2AM0
M4D)RSR`<U%7,=D#_`+N[I:C\46HJ+1N@**H&G&Z@$K6DHX^KF5.6&7IA:K/.
M&HC;YTP<H8JC?!$ELX=<)RBZ=`1=3*KJ+/+/"&J`<KAYS&"O&@Z$K2NJW=9;
M^6[4Y)#E7<@4!1P"!,)!Z))@SM<:(:V_\,EVTK0#,JGM2@KGF6HHSREQQ&$%
M/Z$247*[?,M,E/`?L75]2#1T@;D60426(*2J*P!S%$I@-0:]VI6\9]4A>X-"
MY1*S/,4;1FDXYDF<1%X%*(G;RZ,5S93WU0`L*$DD9)8`]I@A.4\:9YZ5F[*1
MS19-NOYW#\U.2*K)XR`ZL-(6M+*BY<P=Q+D`S>)>M5%E?`,L8I0$0&@ZEVT7
MO1OB1VVI=*W:J12ZNIFQZJO5]=*<H5CB4F0X<X@2]:1U[X6-VW=866G76:->
M<40L>M-IPS*5`<%)GAA*%,#]=;:N2T$Y<T!>871Y0J@VJ#,`;^;\,!,W"XA1
M]UBW!3AXGU>74`_[0]UA<C39Z+W+O)!T/)RA$Y3E/C+&4$\?')M/\*-0VU7*
MN:4B;'<JF5D<C*4@><)DV)BS/'5BW3(YDNBWI&VL.1LS&!(2L@"Q(>/M.'4!
M5O!VNL)2(3$D^!),7!VYC$Y@&H:(2_Z@T=X:MME:4M=2W5ZOJ`2L(Q]=0*9S
M&(2)P,MCT5KWQ2;NC6E^IW*32*%)""J8`;000`#S,L8=B_`]O?!?P#[L;_"W
MP_\`#?NKPR^7]U>4\KY;P^SD\/NUSH^(U/Q#XM,^]][WD^>;-FCJQ\'HO@WP
M'(GW#N.YERRY<O9PCP+MPSBB_P!\UDK]Q;CN^)!F@+9K(7A9ELW,_:MQ`0\!
ML\G(Q^X01H(U*0P%]6FTM?<Z`$4-2ZU/CE4I,_S2(NG[=0U/]^A*_I`'T@Q2
MT\,8GL.2<RMBXLQW8\@Z;$:.9"T+*M>VI!TV34%4C99["1C%RJW(H/,!#&$M
M>[2K*^X5K815ONN@&<EJ4K](F&T]!1TKOO%.TA#TI3"4C#R`1TXI3`%!XAZZ
M5IZ!U9J2%24!)47RR#(CC..?7KB;&>15F#J_<<6%?#B*342C5KPL^W+G69)+
M&*=9%FK.1KY1HFJ8H"8$Q*!A#CJ]IZZMHD%-&\ZV"<<JE)G^:1%D_14M4^%U
M+:%I`YI!](,>=:V#<,V/-)W%9.(,8V=/H(+M6\[:]A6G;TNBU=E*5VV2DH>)
M9ODV[HA`!1,%`(H``!@&FF/7&YUP+5>\ZXSRS+4K](F&M6ZBI5=[2-MH>Z0E
M(]`$=0*4X_6*``(C6@_EU;(GE(.'1V1>Y&Y3_&^>.873A'#]\ROOV]L2XRO"
M:%(&YI>Z+#M2X94Z!!`$T32,Q$O'HI%`H4+S\H4U<IN-TI&.ZH7W4#H"U)'F
M!`BS>H*2K,ZMIM?:E)](,;+:EAV=848:'L.S[6LJ)47.Y4B;4@(BVXX[E01%
M1R=E"M&34RYQ&IC"7F-WCKR=J*JJJ>_K'%N'+*:B5'SDDRBZIV*:F1W;*$H1
MU``>881ZMPVY!77$.X*Y82'N*%D"`D_AY^,93$4\2[R.HZ00<LW)?T5"&+JB
M'7F7$NL*4EQ)P()!\XD1"<;:>3W;R0IOH(F/ECD9=L6W$H<OV><'#3A[.*+`
M`*4H%`^'^&L@J]7P^S65`_Q'/UHL%6NU@^K2LD?01^"*_9CVX?Y>,'_X46!_
M=[3?C-]_?:C_`#'/UHI\,MO[HQ^8C]6*?9CVX?Y>,'_X46!_=[2^,W[]]J/\
MQS]:%\,MO[HQ^8C]6-BA<)XEMATQ>6QB['=N.HT_/'N8.RK9BEF!^Y1B=C&(
M&:*%[C$$HAKU?OEZK*55)6U=0ZTKB%.+(\Q,8ZGTKIRDN*;NQ04R;D,.\#:`
MK'CZP$XT?(>TW;QE=\I*Y!Q%9EQ2JJAE%9%6);,GZYS``&5=O(XK5=TH8`XB
MH8XZS5DW$USIAD4MCN-2U2@8("_5'6`9R\DHP=]VJV[U'5*K;S::.HJUF:E*
M0`3VRE/RX]<=`L'$6.L6L0CL=V-:UGM@1(V-[BAHY@Y60)02D=OD&Y'CR@A7
M^<.;6%NVH+_J&H557ZK>J5JG@M1(GV3D/)&>L>D],Z;9[BP4%-1I`XMH2#YP
M)R\L;I*P[&;8.8J7C6,I&O41;NX^0:MWC)RD(@(I.6CDBC==$1+42F*(5`.&
ML6TX_2+0[1*+;[9FE:3)23U$8CR1EZFD8N%&JDN#:7:=8DM"@"E0ZP<#'D6Q
M8]K6:V79VK;%NVPT=*F7<M;=AXZ&;N%C\3*K(QS9LFHJ(]IC`(ZNZRXW&XO"
MHN#[KSR1(%:E*,NU1)BRMU@LMGIS2VBF:IF'#-:6TI2)]@`CT9VW(>Y(Y>*G
MH:*G(QP6B\9,,6TDQ<4#AXC5XFLW,/K$NK:EJJ^BJ/>J)Y3-1^4@E)EVB4>]
M=:K;=:<4-S9;?HOR5I"AVX@P6H-C6U'WN,\."[$"346\RHH6-+Y?Q:\W!@8?
M(`3F'ZH)@7U4UO+>Z6XS=+[F+Q5]QT9SZ>,1PK8S:85AKF[)1IJ2J>8(D9]/
M1!EH*VX2V(MM"VY#Q<#$M0Y6\9#L6D8P0`:5\)HR210(8:<1`O'6D5=157&L
M-=<'G'J@\2M142>TDQ)5);J"W4J:"W,ML4:1[*`$CS"4>_ZM>47DL)<HL#GK
MQ[/P:45B_2A10U:>SVU]7Y]*%`"M./;I0HKI0H&E"@:4*!I0H&E"@:4*!I0H
>&E"@:4*!I0H&E"@:4*!I0H&E"@:4*!I0H&E"C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
